Ian Dunn to Prognosis
This is a "connection" page, showing publications Ian Dunn has written about Prognosis.
Connection Strength
1.908
-
Chordoma: Genetics and Contemporary Management. Int J Mol Sci. 2024 May 28; 25(11).
Score: 0.192
-
Primary versus secondary gliosarcoma: a systematic review and meta-analysis. J Neurooncol. 2022 Aug; 159(1):195-200.
Score: 0.168
-
The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age. J Neurooncol. 2022 Jul; 158(3):405-412.
Score: 0.167
-
The prognostic significance of further genotyping H3G34 diffuse hemispheric gliomas. Cancer. 2022 05 15; 128(10):1907-1912.
Score: 0.164
-
H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. J Neurooncol. 2021 Dec; 155(3):225-234.
Score: 0.161
-
Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis. Cancer Med. 2021 07; 10(13):4415-4423.
Score: 0.156
-
Consolidating the Hyams grading system in esthesioneuroblastoma - an individual participant data meta-analysis. J Neurooncol. 2021 May; 153(1):15-22.
Score: 0.154
-
The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. BMC Cancer. 2020 Sep 21; 20(1):897.
Score: 0.149
-
Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. World Neurosurg. 2016 Jan; 85:96-105.
Score: 0.104
-
A molecularly integrated grade for meningioma. Neuro Oncol. 2022 05 04; 24(5):796-808.
Score: 0.042
-
Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. Sci Rep. 2021 09 09; 11(1):18009.
Score: 0.040
-
Postoperative Day 1 Morning Cortisol Value as a Biomarker to Predict Long-term Remission of Cushing Disease. J Clin Endocrinol Metab. 2021 01 01; 106(1):e94-e102.
Score: 0.038
-
Impact of insurance on hospital course and readmission after resection of benign meningioma. J Neurooncol. 2020 Aug; 149(1):131-140.
Score: 0.037
-
Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. World Neurosurg. 2020 Jan; 133:e804-e812.
Score: 0.035
-
Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 2019 01 14; 21(Suppl 1):i18-i31.
Score: 0.033
-
Molecular and translational advances in meningiomas. Neuro Oncol. 2019 01 14; 21(Suppl 1):i4-i17.
Score: 0.033
-
Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma. Cancer Med. 2019 01; 8(1):13-20.
Score: 0.033
-
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017 Oct 19; 19(11):1511-1521.
Score: 0.030
-
Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. J Clin Neurosci. 2016 Dec; 34:246-251.
Score: 0.028
-
A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
Score: 0.026
-
Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
Score: 0.026
-
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16.
Score: 0.025
-
Local control after fractionated stereotactic radiation therapy for brain metastases. J Neurooncol. 2014 Nov; 120(2):339-46.
Score: 0.024
-
Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
Score: 0.024
-
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun. 2007 Aug 13; 7:12.
Score: 0.015